A cheap vaccine might be produced on a large scale in a few years. Developed by scientists at the University of Oxford, it might represent a turning point in the fight once morest the disease, said an international research team recently in the journal Lancet Infectious Diseases. Malaria, a parasitic disease transmitted by mosquitoes, killed 627,000 people – mostly African children – in 2020 alone.
Last year another vaccine, produced by British pharmaceutical giant GSK, became the first malaria vaccine to be recommended for widespread use by the World Health Organization (WHO). It has since been given to more than one million children in Africa. But research has shown that the effectiveness of GSK’s vaccine is around 60% and drops dramatically over time, even with a booster dose.
Oxford’s R21/Matrix-M vaccine was found to be 77% effective in preventing malaria, according to a study published last year. This is the first time that a vaccine has exceeded the efficacy target set by the WHO at 75%.
“Much more efficient”
For the study, 450 children aged five to 17 months in Burkina Faso – where malaria accounts for around 22% of all deaths – received three doses in 2019. They were divided into three groups: two received different doses of the Matrix-M adjuvant, a vaccine ingredient patented by Novavax and also used in the American biotechnology company’s Covid vaccine; the third control group received a rabies vaccine. Before the 2020 rainy season (when malaria cases increase), 409 children returned for a booster shot.
For the group that received the highest dose of adjuvant, the effectiveness of the vaccine increased to 80%, according to the results of a phase 2 trial published in early September. For the lowest dose, the efficacy was 70%.
Importantly, one month following receiving the booster, antimalarial antibodies returned to a level similar to that seen following the first doses received a year earlier, according to the study.
“It’s fantastic to see such high efficacy following a single booster dose,” said one of the study’s authors, Halidou Tinto, from the Burkina Faso Health Research Institute, IRSS. Mr Tinto, who was involved in the trial of both malaria vaccines, said GSK’s vaccine had an optimal efficacy of around 60%. “I can therefore confirm that R21 (the Oxford vaccine) is much more effective,” he told a press conference.
“By 2030”
“We might see a very substantial reduction in this horrible burden of malaria, a reduction in deaths and illnesses in the years to come, certainly by 2030”, for his part hoped Adrian Hill, vaccine specialist at Oxford and co-author of the study. According to him, a 70% reduction in malaria deaths might be achievable within that timeframe, in part thanks to the large number of vaccine doses that might be produced quickly.
Oxford has partnered with the world’s largest vaccine maker, the Serum Institute of India. The institute “aims and is able to manufacture 200 million doses per year starting next year,” Hill said. The six to ten million doses that GSK can produce per year are “not enough for 40 million children who need four doses in the first year”, he said. And Oxford’s vaccine would likely cost a few US dollars per dose, less than half the $9 for GSK’s version, he added.
Results from a phase 3 trial involving 4,800 participants in four countries are expected later this year, which might potentially lead to approval of the vaccine.
Daniel LAWLER/AFP
A cheap vaccine might be produced on a large scale in a few years. Developed by scientists at the University of Oxford, it might represent a turning point in the fight once morest the disease, said an international research team recently in the journal Lancet Infectious Diseases. Malaria, a parasitic disease transmitted by mosquitoes, has…
